Breaking News Bar

Business News and Information

The Daily Herald Market Index
Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Recent Quotes
My Watchlist
Indicators
Local Stocks
CALITHERA BIOSCI RG (NQ: CALA)
5.325 USD  +0.025 (+0.47%)
Streaming Delayed Price  /  Updated: 12:59 PM EDT, Jun 25, 2018  /  Add to My Watchlist      
View: Quote News Research
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 124,484
Open 5.200
Bid (Size) 5.300 (1700)
Ask (Size) 5.350 (1000)
Prev. Close 5.300
Today's Range 5.150 - 5.350
52wk Range 4.700 - 20.05
Shares Outstanding 35,844,686
Dividend Yield N/A
Performance
YTD
-40.17%
-40.17%
1 Month
+1.43%
+1.43%
3 Month
-28.04%
-28.04%
6 Month
-35.84%
-35.84%
1 Year
-64.85%
-64.85%
Top News
More News
Calithera to Present at the Jefferies and JMP Securities Healthcare Conferences in June
Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical stage biotechnology company focused on the development of novel cancer therapeutics, announced today Susan M. Molineaux, Ph.D, founder, CEO and... Read More
from GlobeNewswire News Releases
Results from Phase 1 Study of CB-839 in Combination with Capecitabine in Advanced Solid Tumors to be Presented at the 2018 American Society of Clinical Oncology (ASCO)
Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical stage biotechnology company focused on the development of novel cancer therapeutics, announced today that clinical data from its lead product... Read More
from GlobeNewswire News Releases
More News
Read More
Research Report Identifies Monster Beverage, Infinera, Zynga, Calithera Biosciences, Marathon Oil, and National Instruments with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
from GlobeNewswire News Releases
Calithera Biosciences Reports First Quarter 2018 Financial Results and Recent Highlights
from GlobeNewswire News Releases
Technical Snapshots for These Biotech Stocks -- BioPharmX, bluebird bio, Calithera Biosciences, and Capricor Therapeutics
from PR Newswire
Calithera Biosciences Announces CB-839 Abstracts Accepted for Presentation at ASCO 2018
from GlobeNewswire News Releases
Calithera Biosciences Announces FDA Fast Track Designation Granted to CB-839 in Combination with Cabozantinib for Treatment of Patients with Advanced Renal Cell Carcinoma
from GlobeNewswire News Releases
Calithera Biosciences to Present New Preclinical Data for CB-839 at AACR Annual Meeting 2018
from GlobeNewswire News Releases
Calithera to Present at Needham & Company 17th Annual Healthcare Conference
from GlobeNewswire News Releases
Look Under The Hood: PBSM Has 12% Upside
category ETFs
from ETF Channel
BRIEF-Calithera Biosciences Announces FDA Fast Track Designation Granted To CB-839 In Combination With Cabozantinib For Treatment Of Patients With Advanced Renal Cell Carcinoma
category companyNews
from Reuters: Company News
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
bottom clear
Search DailyHerald.com for articles
More ways to search Daily Herald
Obituaries
Search DailyHerald.com obituaries. » Daily Herald newspaper archive
Find archived newspaper articles back to 1901. »
Digital Subscriptions
Activate Subscriber Access Purchase a Digital Subscription
Home Delivery
Start a New Subscription Manage Account